NR3C2 and digestive system disorder: Numerous non-selective and subtype-selective orthosteric ligands that modify MR signaling have been developed and investigated to treat a variety of digestive diseases (Tables 1, 2); allosteric regulation of MR activity represents a presently untapped reservoir of agents that can be designed or repurposed to alter cell function.